EM-1421
| Title | Journal |
|---|---|
| Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity. | Bioorganic & medicinal chemistry letters 20131115 |
| Phase I study of terameprocol in patients with recurrent high-grade glioma. | Neuro-oncology 20120401 |
| Significant biological role of sp1 transactivation in multiple myeloma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111015 |
| Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. | The Journal of pathology 20110301 |
| Terameprocol (tetra-O-methyl nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in non-small cell lung carcinoma. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110101 |
| Glycosylated nordihydroguaiaretic acids as anti-cancer agents. | Bioorganic & medicinal chemistry letters 20110101 |
| Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid. | Antiviral research 20101201 |
| Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid. | Bioorganic & medicinal chemistry letters 20090815 |
| Lignans with anti-HIV activity from Schisandra propinqua var. sinensis. | Journal of natural products 20090601 |
| Phase I clinical trial of repeat dose terameprocol vaginal ointment in healthy female volunteers. | Sexually transmitted diseases 20080601 |
| New nordihydroguaiaretic acid derivatives as anti-HIV agents. | Bioorganic & medicinal chemistry letters 20080315 |
| Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. | IDrugs : the investigational drugs journal 20080301 |
| Phase I/II clinical safety studies of terameprocol vaginal ointment. | Gynecologic oncology 20071201 |
| The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration. | Anti-cancer drugs 20070901 |
| Survivin-dependent and -independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid. | Seminars in oncology 20060801 |
| Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050615 |
| CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. | The American journal of surgical pathology 20050301 |
| Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase. | Journal of medicinal chemistry 20020606 |
| tetra-O-methylnordihydroguaiaretic acid inhibits melanoma in vivo. | Cancer letters 20010928 |
| Johns Hopkins embroiled in fresh misconduct allegations. | Nature 20010802 |
| Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo. | Cancer research 20010715 |
| Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation. | Journal of medicinal chemistry 19980730 |
| Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. | Journal of medicinal chemistry 19980730 |